Article
Immunology
Yamin Shu, Jing Chen, Yiling Ding, Qilin Zhang
Summary: This study evaluated risankizumab-associated adverse events (AEs) and characterized the clinical priority through data mining of the FDA Adverse Event Reporting System (FAERS). The study found potential new AE signals and provided valuable evidence for clinicians to mitigate the risk of risankizumab-associated AEs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Neurosciences
Yamin Shu, Yiling Ding, Lulu Liu, Qilin Zhang
Summary: This study evaluated the association between quetiapine and rare cardiac adverse events (AEs) through data mining of the FDA Adverse Event Reporting System (FAERS). The results showed a high number of rare cardiac AEs, with 13 being identified as new and unexpected signals. The study provided valuable evidence for healthcare professionals to mitigate the risk of quetiapine-associated cardiac AEs.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Oncology
Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang
Summary: This study extensively characterized the hematological toxicities of PARPis based on real-world data and found that these drugs could induce severe organ system toxicities, particularly in the hematological system. We identified that hematological toxicities preferentially occurred early in treatment and could result in serious outcomes.
Article
Pharmacology & Pharmacy
Qi Wang, Jingfang Liu, Hao Sun, Yongfei Dong, Weiliang Tan, Zaixiang Tang, Yiguo Jiang
Summary: This study compared the adverse event profiles of four CGRP monoclonal antibodies using FAERS database. It found that these antibodies had shared signals of adverse events in various organs and systems, including the gastrointestinal and cardiovascular systems, skin, and hair. Particularly in the cardiovascular system, the adverse event profiles of the four antibodies varied significantly.
EXPERT OPINION ON DRUG SAFETY
(2023)
Article
Pharmacology & Pharmacy
Zhihong Fang, Zhiqiang Xu, Wei Zhu, Mingming Yu, Chunmei Ji
Summary: Through data mining of the United States Food and Drug Administration Adverse Event Reporting System, we assessed the safety profiles of apalutamide in the real-world. Common adverse events observed in patients receiving apalutamide included rash, fatigue, diarrhea, hot flush, and fall. The most significant system organ class was skin and subcutaneous tissue disorders, mainly consisting of dermatological adverse events.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Haoning Guo, Bin Wang, Shuying Yuan, Silin Wu, Jing Liu, Miaoquan He, Jisheng Wang
Summary: This study aims to detect and characterize neurological safety signals of esketamine using the FDA pharmacovigilance database. The results show that the associations between esketamine and nervous system disorders persist when stratifying by sex, age, and reporter type, and the severity of adverse events is influenced by the dosage of esketamine, antidepressant polypharmacy, and co-prescription with benzodiazepines. Several signals are categorized as moderate clinical priority, including sedation, dizziness, and dysgeusia. Additionally, some disproportionality signals not previously detected in clinical trials are found, highlighting the importance of early recognition and management of these discrepancies in clinical treatments.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Dongxuan Li, Jinghui Gou, Jun Zhu, Tongyan Zhang, Feng Liu, Daojun Zhang, Liyang Dai, Wenjun Li, Qinglong Liu, Chunmeng Qin, Qian Du, Songqing Liu
Summary: This study provides a comprehensive landscape of culprit-drugs for severe cutaneous adverse reactions (SCARs) by analyzing reports from the FDA Adverse Event Reporting System database. It reveals the risk characteristics of different drugs and may help optimize patient management.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yan Wu, Meihao Wei, Jing Zhang
Summary: The adverse drug event (ADE) signals of upadacitinib were mined from the FDA Adverse Event Reporting System (FAERS) database to provide evidence for its safe clinical use. Several ADEs occurred more frequently in systems not covered in the drug labeling information, including renal and urinary system, reproductive and breast diseases, ear and labyrinth disorders, psychiatric disease, blood and lymphatic system disorders, and endocrine disorders. High-frequency events leading to serious adverse events were mainly related to urinary tract infection, herpes zoster, diverticulitis, and bronchitis.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Milo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger, Fabrizio De Ponti, Emanuel Raschi
Summary: This study aimed to characterize the clinical priority of adverse events associated with sacubitril/valsartan and found an increased reporting of cardiovascular adverse events with significant clinical priorities. Notably, sudden cardiac death was observed early after sacubitril/valsartan administration, highlighting the need for strict clinical monitoring and further investigation into potential drug interactions.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Renjun Yang, Nuoya Yin, Ying Zhao, Dandan Li, Xuanling Zhang, Xingang Li, Yang Zhang, Francesco Faiola
Summary: This study found a strong signal for an increased risk of spontaneous abortion in HBV-infected patients using ETV or ADV, compared to those prescribed with LAM. However, no obvious signal of human teratogenicity was identified in fetuses exposed to ETV or ADV during pregnancy. Further well-designed comparative safety studies are needed to validate these results in clinical practice.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Chunmei Ji, Jinmei Bai, Jiancheng Zhou, Ying Zou, Mingming Yu
Summary: Background: Proprotein convertase subtilisin/kexin type (PCSK9) inhibitors are a new drug class approved for treating dyslipidemias. In this study, we investigated the safety profiles of PCSK9 inhibitors (alirocumab and evolocumab) using the FDA Adverse Event Reporting System (FAERS). Methods: We analyzed adverse event reports submitted to FAERS from 2015Q3 to 2021Q1. Results: The FAERS database documented 31,475 reports regarding PCSK9 inhibitors. Alirocumab and evolocumab had similar safety profiles with common adverse events including injection-site reactions, muscle-related AEs, and influenza-like illness. Conclusion: Data mining of FAERS proved useful in examining PCSK9 inhibitor-induced AEs, and the findings were consistent with clinical experience, providing insights for improving the safety of these drugs in clinical practice.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Huqun Li, Chongshu Wang, Aiping Deng, Cuilian Guo
Summary: The study conducted a disproportionality analysis on mepolizumab-associated adverse events using the FAERS database, identifying 736 significant PTs among 13,497 reports. Commonly reported AEs such as dyspnea, fatigue, and headache were in line with previous studies, while unexpected AEs like cough, malaise, and chest discomfort were also identified. Most AEs occurred within the first month after mepolizumab initiation, and issues such as pneumonia and wheezing were frequently reported with long-term mepolizumab exposure and in pediatric patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Hematology
Mingxing Guo, Jinwei Liang, Dandan Li, Ying Zhao, Wanyi Xu, Lei Wang, Xiangli Cui
Summary: This study found an association between tigecycline and coagulation dysfunction using the FAERS database. It is important for healthcare professionals to be aware of the potential risk of coagulation disorders and monitor coagulation parameters, especially fibrinogen levels, during antibacterial therapy with tigecycline.
THROMBOSIS JOURNAL
(2022)
Article
Pharmacology & Pharmacy
Bing Cao, Shanshan Gu, Zhisen Shen, Yuna Zhang, Yiming Shen, Hang Chen
Summary: This study collected data from the FAERS database to evaluate the adverse events induced by Ubrogepant. It identified new adverse events that have not been reported before, providing new guidance for understanding the safety of Ubrogepant.
EXPERT OPINION ON DRUG SAFETY
(2023)
Article
Medicine, Research & Experimental
Austin R. Swisher, Rijul S. Kshirsagar, Nithin D. Adappa, Jonathan Liang
Summary: The study evaluated the adverse reactions of dupilumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP). Analysis of FAERS data showed that CRSwNP-tx had fewer individual DAR compared to other treatment indications, with women and older adults experiencing more iDAR, while men tended to have more serious DAR.